GENETIC DISORDER ALZHEIMER
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i12.18684Keywords:
Nil, Beta-amyloid protein, Memory loss, HypercholesteremiaAbstract
Alzheimer's disease (AD), slowly continuous neurological disorder, mostly appears in older >65 age that deals with the memory loss due to death or damage of brain cells and cognitive functions (thinking, reasoning, and behavior abnormalities) due to the accumulation of the specific protein (beta-amyloid protein) which form plaque and fibers (tau tangles) in the brain. Not only the genetic factors are responsible but also most of the non-genetic factors are responsible for AD. Several mutations in the gene (APP, APOE, PENS1, PENS2 on chromosome no. 21, 19, 14, 1) are responsible for causing four types of AD. Memory loss is most common sign of AD. Predisposing factors of AD are hereditary, severe brain injury or traumatic, and metabolic diseases such as diabetes mellitus, hypercholesteremia, and obesity. Although treatment can manage some symptoms in few people, but there is no current mechanism to cure AD or stop its progression. Beta-secretase inhibitor molecule prevents the first step in a chain accumulation which leads to the formation of amyloid plaque in the brain. However, the scientist or researchers have established a compound NIC5-15 they have been found NIC5-15 has safe and effectual treatment which has been used to stabilize cognitive performance in patients with mild to moderate AD.
Downloads
References
Bird TD. Genetic aspects of Alzheimer disease. Genet Med 2008;10(4):231-9.
Jack CR Jr. Alzheimer disease: New concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263(2):344-61.
Gadit AA. State of mental health in Pakistan. J Pak Med Assoc 2001;51(7):238-9.
Hampel H, Prvulovic D, Teipel S, Jessen F, Luck-Haus C, Frolich L, et al. The future of Alzheimer’s disease: The next 10 years. Prog Neurobiol 2011;95:718-28.
Kung HF. The ß-amyloid hypothesis in Alzheimer’s disease: Seeing is believing. ACS Med Chem Lett 2012;3(4):265-7.
Contino M, Cantore M, Leopoldo M, Colabufo N. Biomarkers for the early diagnosis of Alzheimer’s disease: The challenge of XXI century. Adv Alzheimer’s Dis 2013;2:13-30.
Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137-52.
Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013;266(2):583-91.
Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid ß peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 2013;38(1):6-23.
Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician 2011;83(12):1403-12.
Bekris LM, Galloway NM, Montine TJ, Schellen-Berg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 2010;153B:409-17.
Duthey B. Alzheimer Disease and Other Dementias; 2013.
Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 1989;262(18):2551-6.
Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T. Post stroke dementia: Clinical features and risk factors. Stroke 2000;31:1494-501.
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-31.
Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010;67:308-16.
Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid beta protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002;22:4833-41.
Yao ZX, Papadopoulos V. Function of beta-amyloidin cholesterol transport: A lead to neurotoxicity. FASEB J 2002;16:1677-9.
Maloney B, Lahiri DK. The Alzheimer’s amyloid ß-peptide (Aß) binds a specific DNA Aß-interacting domain (AßID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. Gene 2011;488(1-2):1-12.
Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010;5(3):e9505.
Klein WL. Synaptotoxic amyloid-ß oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease? J Alzheimers Dis 2013;33 Suppl 1:S49-65.
Frosch MP, Anthony DC, Girolami UD. The central nervous system. In: Robbins SL, Kumar V, Abbas AK, Cotran RS, Fausto N, editors.
Robbins and Cotran Pathologic Basis of Disease. Philadelphia, PA: Elsevier; 2010. p. 1313-7.
Roher AE, Maarouf CL, Sue L, Hu Y, Jeffrey W, Wilson J, et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers 2009;14:493-501.
Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71(2):85-92.
Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: A community based follow up study. J Neurol Neurosurg Psychiatry 1998;64(3):298-305.
Arai D, Terajima M, Miura M, Higuchi S, Muramatsuet T, Machida N, et al. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer’s disease. Ann Neurol 1995;38:649-52.
Ghanbari H, Ghanbari K, Munzar M, Paul MD, Averback MD. Specificity of AD7C-NTP as a biochemical marker for Alzheimer’s disease. Neurol Clin Neurophysiol 1998; 12(5):285-298.
Alzheimer’s Disease International. Drug Treatment in Dementia, Fact Sheet 8, Updated April; 2000. Available from: http://www.alz.co.uk/adi/publications.html#factsheets. [Last accessed on 2004 Mar 09].
Suemoto T, Okamura N, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, et al. In vivo labeling of amyloid with BF-108. Neurosci Res 2004;48(1):65-74.
Chen WP, Samuraki M, Yanase D, Shima K, Takeda N, Ono K, et al. Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer’s disease using automated image analysis. Nucl Med Commun 2008;29(3):270-6.
Nestle U, Kotzerke J. PTV-PET traced volume? Nuklearmedizin 2009;48(4):127-9.
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68(20):1718-25.
Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129:2856-66.
Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002;23(4):485-508.
Pirttila T, Mehta PD, Frey H, Wisniewski HM. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer’s disease. Neurobiol Aging 1994;15(3):313-7.
Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 2010;68:930-41.
Devi S, Singh K. Risk factors, prevalence and diagnosis of hutchison gilford syndrome with special reference to case reports. Int J Pharm Pharm Sci 2017;9(5):1-5.
Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 2012;124(3):305-23.
Diaz-Arrastia R, Baskin F. New biochemical markers in Alzheimer disease. Arch Neurol 2001;58(3):354-6.
Ferencz B, Karlsson S, Kalpouzos G. Promising genetic biomarkers of preclinical Alzheimer’s disease: The influence of APOE and TOMM40 on brain integrity. Int J Alzheimers Dis 2012;2012:15.
Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1996;8(3):270-5.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
Vitiello MV, Bliwise DL, Prinz PN. Sleep in Alzheimer’s disease and the sundown syndrome. Neurology 1992;42 7 Suppl 6:83-93.
Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54(7):836-40.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975;72(5):1858-62.
Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 1986;387(3):271-80.
Peera K, Yellamma K. Sericin as a cholinergic modulator in Alzeimer’s disease induced rat. Int J Pharm Pharm Sci 2015;7(4):108-12.
Abd El Dayem SM, Metwally FT, Ahmed HH, Foda FM, Shalby AB, Zaazaa AM. Perspective in the treatment of Alzheimer’s disease: Pre-clinical study. Int J Pharm Pharm Sci 2014;6(11):482-6.
Chen W, Shi L, Qian Y. Substance flow analysis of aluminium in mainland China for 2001, 2004 and 2007: Exploring its initial sources, eventual sinks and the pathways linking them. Resour Conserv Recycl 2010;54(9):557-70.
Al-Hashem F. Camel’s milk protects against aluminum chlorideinduced toxicity in the liver and kidney of white albino rats. Am J Biochem Biotechnol 2009;5(3):98-109.
Sharma P, Mishra K. Amelioration of fumonisin B1 hepatotoxicity in mice by depletion of T cells with anti-Thy-1.2. Reprod Toxicol 2006;21:313-21.
Abbasali KM, Zhila T, Farshad N. Developmental toxicity of aluminum from high doses of AlCl3 in mice. J Appl Res 2005;5:575-9.
Miu AC. A behavioral and histological study of the effects of long-term exposure of adult rats to aluminum. Int J Neurosci 2003;113:1197-211.
Campbell A. Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma but not in glioma cells. Proc Soc Exp Biol Med 2000;223:397-402.
Savory J. Intracellular mechanisms underlying aluminum induced apoptosis in Rabbit brain. J Inorg Biochem 2003;97:151-4.
Shati AA, Elsaid FG, Hafez EE. Biochemical and molecular aspects of aluminium chloride-induced neurotoxicity in mice and the protective role of Crocus sativus L. extraction and honey syrup. Neurosciences 2011;175(17):66-74.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
